Mylan Nifedipine Settlement Revised Certification To Paragraph III, FDA Says

Mylan effectively amended its patent certification for its 30 mg extended-release nifedipine from paragraph IV to paragraph III by entering into an agreement with Pfizer to market "authorized generic" variants of Procardia XL and failing to launch its own approved version of the drug, FDA said Feb. 6.